Jaguar Health, Inc. (NASDAQ:JAGX) is inviting investors to join a live webcast on March 27, 2023, to review the fourth-quarter 2022 financials and get a corporate update. The webcast starts at 8:00 a.m. Eastern Daylight Time, so don’t miss out on this opportunity to learn more about the company’s progress and financial performance!
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is revolutionizing the way people and animals suffering from gastrointestinal distress can find relief. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is leading the charge in creating plant-based, sustainably derived prescription medicines.
Our crofelemer drug product candidate is currently undergoing a pivotal Phase 3 clinical trial, the OnTarget study, which seeks to prophylaxis diarrhea in adult cancer patients receiving targeted therapy.
Moreover, Jaguar Health has established Napo Therapeutics S.p.A. in Milan, Italy to expand crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health and continues to be an integral part of the company’s innovative mission.